Spanish dermatology specialist Almirall (BME: ALM) was trading 4% higher at the end of Monday’s trading day in Barcelona.
Almirall earlier announced its financial results from the first half of 2024, delivering strong sales growth in the second quarter of the year, which was mainly driven by the dermatology business in Europe.
Total net sales for the six-month period increased by 6.7% to a total of 497.2 million euros ($541.2 million), while earnings before interest, taxes, depreciation and amortization (EBITDA) were 104.5 million, a rise of 3.2%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze